Quell Therapeutics Ltd, recently formed to engineer regulatory T cells (Tregs) to overcome autoimmune and inflammatory diseases as well as immune dysfunction, has appointed Iain McGill as chief executive. Mr McGill previously was a senior executive for Jazz Pharmaceuticals Plc. He will be working with six professors from three UK universities who are specialists in Tregs or related fields. Quell Therapeutics was founded by Syncona Ltd, a venture organisation whose largest shareholder is the Wellcome Trust, UK. Syncona provided £34 million of Series A funding while the University College London Technology Fund invested £1 million.
Quell Therapeutics announced the appointment on 13 June 2019.
Copyright 2019 Evernow Publishing Ltd